However, the use of MAO-B inhibitors was associated with a lower increase in the UPDRS scores for dyskinesias (p = 0.028; Table 3) and lower prevalence of dyskinesias at follow-up (Fig. 2, plot a), with an OR for rasagiline of 0.47 (95% CI 0.28–0.81; p = 0.006) and 0.53 for selegiline (95% CI 0.31–0.90; p = 0.019). Here, MAOB is linked to Dyskinesia.